These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 30535563)

  • 1. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis.
    Ge F; Lin H; Li Z; Chang T
    Neurol Sci; 2019 Mar; 40(3):479-487. PubMed ID: 30535563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis.
    Zhang P; Liu B
    Bone Marrow Transplant; 2020 Oct; 55(10):1928-1934. PubMed ID: 32020080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
    Muraro PA; Pasquini M; Atkins HL; Bowen JD; Farge D; Fassas A; Freedman MS; Georges GE; Gualandi F; Hamerschlak N; Havrdova E; Kimiskidis VK; Kozak T; Mancardi GL; Massacesi L; Moraes DA; Nash RA; Pavletic S; Ouyang J; Rovira M; Saiz A; Simoes B; Trnený M; Zhu L; Badoglio M; Zhong X; Sormani MP; Saccardi R;
    JAMA Neurol; 2017 Apr; 74(4):459-469. PubMed ID: 28241268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
    Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
    Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
    Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
    Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.
    Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA
    Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
    Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
    Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis.
    Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kartashov AV; Kurbatova KA; Gorodokin GI; Novik AA
    Exp Hematol; 2012 Nov; 40(11):892-8. PubMed ID: 22771495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Sormani MP; Muraro PA; Schiavetti I; Signori A; Laroni A; Saccardi R; Mancardi GL
    Neurology; 2017 May; 88(22):2115-2122. PubMed ID: 28455383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis.
    Nabizadeh F; Pirahesh K; Rafiei N; Afrashteh F; Ahmadabad MA; Zabeti A; Mirmosayyeb O
    Neurol Ther; 2022 Dec; 11(4):1553-1569. PubMed ID: 35902484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
    Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
    Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
    Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
    Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series.
    Nicholas RS; Rhone EE; Mariottini A; Silber E; Malik O; Singh-Curry V; Turner B; Scalfari A; Ciccarelli O; Sormani MP; Olavarria E; Mehra V; Gabriel I; Kazmi MA; Muraro P;
    Neurology; 2021 Aug; 97(9):e890-e901. PubMed ID: 34253634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.
    Bayas A; Berthele A; Blank N; Dreger P; Faissner S; Friese MA; Gerdes LA; Grauer OM; Häussler V; Heesen C; Janson D; Korporal-Kuhnke M; Kowarik M; Kröger N; Lünemann JD; Martin R; Meier U; Meuth S; Muraro P; Platten M; Schirmer L; Stürner KH; Stellmann JP; Scheid C; Bergh FT; Warnke C; Wildemann B; Ziemssen T
    Ther Adv Neurol Disord; 2023; 16():17562864231180730. PubMed ID: 37780055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up more than 10 years after HSCT: a monocentric experience.
    Frau J; Carai M; Coghe G; Fenu G; Lorefice L; La Nasa G; Mamusa E; Vacca A; Marrosu MG; Cocco E
    J Neurol; 2018 Feb; 265(2):410-416. PubMed ID: 29270686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis.
    Shouval R; Furie N; Raanani P; Nagler A; Gafter-Gvili A
    Biol Blood Marrow Transplant; 2018 May; 24(5):937-944. PubMed ID: 29374527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience.
    Currò D; Mancardi G
    Neurol Sci; 2016 Jun; 37(6):857-65. PubMed ID: 27071689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous hematopoietic stem cell transplantation of patients with aggressive relapsing-remitting multiple sclerosis: Danish nation-wide experience.
    Jespersen F; Petersen SL; Andersen P; Sellebjerg F; Magyari M; Sørensen PS; Blinkenberg M
    Mult Scler Relat Disord; 2023 Aug; 76():104829. PubMed ID: 37364374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of autografting persons with multiple sclerosis are better in those not exposed to prior disease-modifying therapies.
    Sánchez-Bonilla D; Robles-Nasta M; Gallardo-Pérez MM; Hernández-Flores EJ; Montes-Robles M; Pastelín-Martínez ML; Garcés-Eisele SJ; Olivares-Gazca JC; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Mult Scler Relat Disord; 2023 Jul; 75():104744. PubMed ID: 37178580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.